Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 16/20 | 0.58 |
| ▸ | MAOA | P21397 | 1/20 | 0.58 |
| ▸ | GRM5 | P41594 | 8/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.46 |
| ▸ | RELA | Q04206 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL56658 | 0.87 | MAOB (0.46) | MAOBMAOAGRM5NPC1ALDH1A1 | |
| SCHEMBL9076881 | 0.86 | MAOB (0.62) | MAOBMAOAGRM5NPC1ALDH1A1 | |
| SCHEMBL2223184 | 0.83 | MAOB (0.58) | MAOBMAOAGRM5NPC1ALDH1A1 | |
| SCHEMBL5114795 | 0.83 | MAOB (0.58) | MAOBMAOAGRM5NPC1ALDH1A1 | |
| SCHEMBL3900510 | 0.83 | MAOB (0.58) | MAOBMAOAGRM5NPC1ALDH1A1 | |
| SCHEMBL20165396 | 0.83 | MAOB (0.63) | MAOBMAOAGRM5NPC1ALDH1A1 | |
| SCHEMBL69427 | 0.83 | MAOB (0.43) | MAOBMAOAALDH1A1 | |
| SCHEMBL1987729 | 0.83 | MAOB (0.54) | MAOBMAOAGRM5NPC1ALDH1A1 | |
| SCHEMBL10364085 | 0.83 | MAOB (0.54) | MAOBMAOAGRM5NPC1ALDH1A1 | |
| SCHEMBL2953711 | 0.80 | GRM5 (0.57) | MAOBMAOAGRM5NPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12583858-B2 | TDO2 inhibitors | GENENTECH, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| EP-3994125-B1 | MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF | REGENERON PHARMA (US) | 2025-12-24 | — | — | EP | disclosed |
| CN-115836077-B | Oxazaspiro derivative, preparation method thereof and application thereof in medicine | 江苏恒瑞医药股份有限公司 | 2025-05-13 | — | — | CN | disclosed |
| US-20240299402-A1 | MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2024-09-12 | — | — | US | disclosed |
| EP-3394068-B1 | TDO2 INHIBITORS | GENENTECH INC (US) | 2024-09-11 | — | — | EP | disclosed |
| US-11957687-B2 | Modulators of HSD17B13 and methods of use thereof | REGENERON PHARMACEUTICALS, INC. (US) | 2024-04-16 | — | — | US | disclosed |
| US-20230234962-A1 | OXA-AZASPIRO DERIVATIVE, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) | 2023-07-27 | — | — | US | disclosed |
| CN-113754685-B | Dihydrothiochromene pyrazole derivative, preparation method and application thereof in medicine | 江苏恒瑞医药股份有限公司 | 2023-06-16 | — | — | CN | disclosed |
| EP-4190789-A1 | OXA-AZASPIRO DERIVATIVE, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2023-06-07 | — | — | EP | disclosed |
| US-20230094341-A1 | MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2023-03-30 | — | — | US | disclosed |
| EP-2042573-A1 | Ink composition | FUJIFILM Corporation (JP) | 2009-04-01 | — | — | EP | disclosed |
| US-20090081421-A1 | PHOTOCURABLE COATING COMPOSITION, AND OVERPRINT AND PROCESS FOR PRODUCING SAME | FUJIFILM CORPORATION (JP) | 2009-03-26 | — | — | US | disclosed |
| EP-1975210-A1 | Ink set for inkjet recording and inkjet recording method | FUJIFILM Corporation (JP) | 2008-10-01 | — | — | EP | disclosed |
| US-20080182031-A1 | Sensitizing dye, an alpha-aminoketone or acyl phosphine oxide polymerization initiator and an ethylenically unsaturated bond-containing polymerizable compound | FUJIFILM CORPORATION (JP) | 2008-07-31 | — | — | US | disclosed |
| EP-1944173-A1 | Ink composition and inkjet recording method using the same | FUJIFILM Corporation (JP) | 2008-07-16 | — | — | EP | disclosed |
| US-5886016-A | ANTIINFLAMMATORY AGENT WITH MINIMAL SIDE EFFECTS FOR TREATING ARTHRITIS | G.D. SEARLE & CO. (US) | 1999-03-23 | — | — | US | disclosed |
| US-5670532-A | Pyrazolyl derivatives for the treatment of inflammation | G. D. SEARLE & CO. (US) | 1997-09-23 | — | — | US | disclosed |
| US-5565482-A | ANTIINFLAMMATORY AGENTS, ANTIARTHRITIC AGENTS | G.D. SEARLE & CO. (US) | 1996-10-15 | — | — | US | disclosed |
| US-5547975-A | ANTIARTHRIC AGENTS, ANALGESICS AND ANTIPYRETICS; INHIBITORS OF CYCLOOXYGENASE II; SIDE EFFECT REDUCTION | G.D. SEARLE & CO. | 1996-08-20 | — | — | US | disclosed |
| WO-1996009304-A1 | BENZOPYRANOPYRAZOLYL DERIVATIVES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240299402-A1 | MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF | HSD17B3, HSD17B11, HSD17B1 | MAOB 870/4885MAOA 1875/4885GRM5 1523/4885 |
| US-12583858-B2 | TDO2 inhibitors | TDO2, IDO2, TPH2 | MAOB 26/4885MAOA 18/4885GRM5 3952/4885 |
| US-20230234962-A1 | OXA-AZASPIRO DERIVATIVE, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | PIK3CD, PIK3CA, PIK3R5 | MAOB 1445/4885MAOA 1720/4885GRM5 2584/4885 |
| US-20230094341-A1 | MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF | HSD17B3, HSD17B11, HSD17B1 | MAOB 870/4885MAOA 1875/4885GRM5 1523/4885 |
| US-11957687-B2 | Modulators of HSD17B13 and methods of use thereof | HSD17B3, HSD17B11, HSD17B1 | MAOB 870/4885MAOA 1875/4885GRM5 1523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.